Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 30:6:1581694.
doi: 10.3389/falgy.2025.1581694. eCollection 2025.

ULANC - EUFOREA workshop 2024: bringing the concept of global airways to the frontline of medical care

D M Conti  1   2 , V Backer  3 , K Aanaes  3 , A Azizi  4 , P W Hellings  5   6   7 , S Lau  8 , G Liva  9 , G K Scadding  10   11 , S Toppila-Salmi  12   13
Affiliations

ULANC - EUFOREA workshop 2024: bringing the concept of global airways to the frontline of medical care

D M Conti et al. Front Allergy. .

Abstract

The Upper and Lower Airways Northern European Consensus (ULANC) and the European Forum for Research and Education in Allergy and Airways diseases (EUFOREA) organized their first workshop in Copenhagen in January 2024. The aim of the "Primary care physicians and nurses with an interest in Global Airway Diseases 2024" was to bring the concept of the global airway to the front line of medical care. ULANC is a multidisciplinary European consortium, that aims to improve the management of comorbid ear, nose and throat (ENT) conditions, such as chronic rhinosinusitis with nasal polyposis (CRSwNP), in patients also suffering from asthma. EUFOREA is an international non-profit organization forming an alliance of all stakeholders dedicated to reducing the prevalence and burden of chronic respiratory diseases through the implementation of optimal patient care via educational, research, and advocacy activities. The inclusive and multidisciplinary approach of ULANC and EUFOREA was reflected in the keynote lectures and workshop faculty coming from the allergology, pulmonology, ENT, and primary health care fields around the central theme of global airway diseases. The current report aims at providing a comprehensive overview of the key statements by the faculty of the "Primary care physicians and nurses with interest in Global Airway Diseases 2024", allowing all stakeholders in the respiratory field to be up-dated and ready to join forces in Europe and beyond.

Keywords: CRS; EUFOREA; ULANC; allergy; asthma; comorbidities; global airway diseases; primary care.

PubMed Disclaimer

Conflict of interest statement

DC: Serves as academic manager at the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) and as review editor at Frontiers in Allergy, rhinology section. PH: Is recipient of consultancy/lecture fees or unrestricted research grants from Sanofi/Regeneron, Novartis, GSK, Medtronic and Viatris. SL.: Received honoraria for lectures and advisory boards from Sanofi-Aventis, Allergopharma, ALK, GSK, Leo Pharma, Leti, Viatris, Lilly and DBV. ExCom member of the DGAKI (German Society of Allergology and Clinical Immunology) and GPP (Society of Pediatric Pneumology). GS: Honoraria for articles, speaker and advisory boards: ALK, Bayer, GlaxoSmithKline, Haleon, Noucor, Sanofi-Regeneron, and Viatris. Chair of BSACI rhinitis guidelines, Scientific Chief Editor, Rhinology Section of Frontiers in Allergy, Board member and AR lead for EUFOREA, and Chair/member Data Monitoring Committees on SLIT for ALK. SL: Received honoraria for lectures and advisory boards from Sanofi-Aventis, Allergopharma, ALK, GSK, Leo Pharma, Leti, Viatris, Lilly and DBV. ST-S: Reports consultancies for ALK-Abelló, AstraZeneca, ERT, GSK, Novartis, Sanofi, and Roche Products outside the submitted work, as well as grant of GSK outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

References

    1. De Prins L, Raap U, Mueller T, Schmid-Grendelmeier P, Haase CH, Backer V, et al. White paper on European patient needs and suggestions on chronic type 2 inflammation of airways and skin by EUFOREA. Front Allergy. (2022) 3:889221. 10.3389/falgy.2022.889221 Erratum in: Front Allergy. 2022 September 09;3:1001078. doi: 10.3389/falgy.2022.1001078. - DOI - PMC - PubMed
    1. Claeys N, Teeling MT, Legrand P, Poppe M, Verschueren P, De Prins L, et al. Patients unmet needs in chronic rhinosinusitis with nasal polyps care: a patient advisory board statement of EUFOREA. Front Allergy. (2021) 2:761388. 10.3389/falgy.2021.761388 - DOI - PMC - PubMed
    1. Pugin B, Deneyer L, Bachert C, Alobid I, Bousquet J, De Carlo G, et al. Patient advisory board for chronic rhinosinusitis - A EUFOREA initiative. Rhinology. (2019) 57(5):331–5. 10.4193/Rhin19.012 - DOI - PubMed
    1. Seys SF, De Bont S, Fokkens WJ, Bachert C, Alobid I, Bernal-Sprekelsen M, et al. Real-life assessment of chronic rhinosinusitis patients using mobile technology: the mySinusitisCoach project by EUFOREA. Allergy. (2020) 75(11):2867–78. 10.1111/all.14408 - DOI - PMC - PubMed
    1. Teeling T, Djouder C, Laurens H, Preyra JH, Shire CME, Van Staeyen E, et al. Nasal polyp syndrome: a patient-centred term for CRSwNP by EUFOREA. Front Allergy. (2024) 5:1372919. 10.3389/falgy.2024.1372919 - DOI - PMC - PubMed

LinkOut - more resources